{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:27:52Z","timestamp":1778660872209,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Mundiharma K.K"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s00277-023-05157-x","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T08:11:37Z","timestamp":1680163897000},"page":"1149-1158","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real-world data from yttrium-90 ibritumomab tiuxetan treatment of relapsed or refractory indolent B-cell non-Hodgkin's lymphoma: J3Zi Study"],"prefix":"10.1007","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8920-7045","authenticated-orcid":false,"given":"Ilseung","family":"Choi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,30]]},"reference":[{"key":"5157_CR1","unstructured":"Cancer statistics Japan\u00a0(in Japanese).\u00a0https:\/\/ganjoho.jp\/reg_stat\/statistics\/stat\/cancer\/25_ml.html. Accessed 22 Sep 2022"},{"key":"5157_CR2","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1046\/j.1440-1827.2000.01108.x","volume":"50","author":"Lymphoma Study Group of Japanese Pathologists","year":"2000","unstructured":"Lymphoma Study Group of Japanese Pathologists (2000) The world health organization classification of malignant lymphomas in japan: incidence of recently recognized entities. Pathol Int 50:696\u2013702. https:\/\/doi.org\/10.1046\/j.1440-1827.2000.01108.x","journal-title":"Pathol Int"},{"key":"5157_CR3","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/ajh.26151","volume":"96","author":"S Susanibar-Adaniya","year":"2021","unstructured":"Susanibar-Adaniya S, Barta SK (2021) 2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management. Am J Hematol 96:617\u2013629. https:\/\/doi.org\/10.1002\/ajh.26151","journal-title":"Am J Hematol"},{"key":"5157_CR4","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/0360-3016(89)90486-0","volume":"16","author":"S Reddy","year":"1989","unstructured":"Reddy S, Saxena VS, Pellettiere EV, Hendrickson FR (1989) Stage I and II non-Hodgkin\u2019s lymphomas: long-term results of radiation therapy. Int J Radiat Oncol Biol Phys 16:687\u2013692. https:\/\/doi.org\/10.1016\/0360-3016(89)90486-0","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5157_CR5","doi-asserted-by":"crossref","unstructured":"Mac Manus MP, Hoppe RT (1996) Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 14:1282\u201390. https:\/\/ascopubs.org\/doi\/10.1200\/JCO.1996.14.4.1282. Accessed 30 Sept 2022","DOI":"10.1200\/JCO.1996.14.4.1282"},{"key":"5157_CR6","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1182\/blood.V80.4.863.863","volume":"80","author":"ML Grossbard","year":"1992","unstructured":"Grossbard ML, Press OW, Appelbaum FR et al (1992) Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 80:863","journal-title":"Blood"},{"key":"5157_CR7","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/bjh.13493","volume":"170","author":"TE Witzig","year":"2015","unstructured":"Witzig TE, Hong F, Micallef IN et al (2015) A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I\/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402. Br J Haematol 170:679\u2013686. https:\/\/doi.org\/10.1111\/bjh.13493","journal-title":"Br J Haematol"},{"key":"5157_CR8","doi-asserted-by":"publisher","first-page":"204062072198957","DOI":"10.1177\/2040620721989579","volume":"12","author":"M Candelaria","year":"2021","unstructured":"Candelaria M, Due\u00f1as-Gonzalez A (2021) Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma. Ther Adv Hematol 12:2040620721989579. https:\/\/doi.org\/10.1177\/2040620721989579","journal-title":"Ther Adv Hematol"},{"key":"5157_CR9","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/j.1349-7006.2008.00999.x","volume":"100","author":"K Tobinai","year":"2009","unstructured":"Tobinai K, Watanabe T, Ogura M et al (2009) Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma. Cancer Sci 100:158\u2013164. https:\/\/doi.org\/10.1111\/j.1349-7006.2008.00999.x","journal-title":"Cancer Sci"},{"key":"5157_CR10","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1007\/s12185-014-1636-5","volume":"100","author":"N Uike","year":"2014","unstructured":"Uike N, Choi I, Tsuda M et al (2014) Factors associated with effects of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory low-grade B cell non-Hodgkin lymphoma: single-institution experience with 94 Japanese patients in rituximab era. Int J Hematol 100:386\u2013392. https:\/\/doi.org\/10.1007\/s12185-014-1636-5","journal-title":"Int J Hematol"},{"key":"5157_CR11","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1248\/yakushi.18-00112","volume":"139","author":"H Yoshikawa","year":"2019","unstructured":"Yoshikawa H, Sakurashita H, Izumitani S, Taogoshi T, Saeki Y, Matsuo H (2019) Safety of 90Y-ibritumomab Tiuxetan treatment for Japanese patients in real-world clinical practice. Yakugaku Zasshi 139:131\u2013134. https:\/\/doi.org\/10.1248\/yakushi.18-00112","journal-title":"Yakugaku Zasshi"},{"key":"5157_CR12","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","volume":"10","author":"CL Batlevi","year":"2020","unstructured":"Batlevi CL, Sha F, Alperovich A et al (2020) Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J 10:74. https:\/\/doi.org\/10.1038\/s41408-020-00340-z","journal-title":"Blood Cancer J"},{"key":"5157_CR13","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1080\/10428190500376076","volume":"47","author":"C Emmanouilides","year":"2006","unstructured":"Emmanouilides C, Witzig TE, Gordon LI et al (2006) Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin\u2019s lymphoma. Leuk Lymphoma 47:629\u2013636. https:\/\/doi.org\/10.1080\/10428190500376076","journal-title":"Leuk Lymphoma"},{"key":"5157_CR14","doi-asserted-by":"publisher","first-page":"e78730","DOI":"10.1371\/journal.pone.0078730","volume":"8","author":"N Yoshida","year":"2013","unstructured":"Yoshida N, Oda M, Kuroda Y et al (2013) Clinical significance of sIL-2R levels in B-cell lymphomas. PLoS One 8:e78730. https:\/\/doi.org\/10.1371\/journal.pone.0078730","journal-title":"PLoS One"},{"key":"5157_CR15","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.cdp.2005.03.001","volume":"29","author":"K Nakase","year":"2005","unstructured":"Nakase K, Tsuji K, Tamaki S et al (2005) Elevated levels of soluble interleukin-2 receptor in serum of patients with hematological or non-hematological malignancies. Cancer Detect Prev 29:256\u2013259. https:\/\/doi.org\/10.1016\/j.cdp.2005.03.001","journal-title":"Cancer Detect Prev"},{"key":"5157_CR16","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1080\/10245332.2017.1312204","volume":"22","author":"K Umino","year":"2017","unstructured":"Umino K, Fujiwara SI, Ikeda T et al (2017) Prognostic value of the soluble interleukin-2 receptor level after patients with follicular lymphoma achieve a response to R-CHOP. Hematology 22:521\u2013526. https:\/\/doi.org\/10.1080\/10245332.2017.1312204","journal-title":"Hematology"},{"key":"5157_CR17","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.clml.2013.03.014","volume":"13","author":"T Yoshizato","year":"2013","unstructured":"Yoshizato T, Nannya Y, Imai Y, Ichikawa M, Kurokawa M (2013) Clinical significance of serum-soluble interleukin-2 receptor in patients with follicular lymphoma. Clin Lymphoma Myeloma Leuk 13:410\u2013416. https:\/\/doi.org\/10.1016\/j.clml.2013.03.014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"5157_CR18","first-page":"170","volume":"43","author":"H Ohno","year":"2002","unstructured":"Ohno H, Ishikawa T, Kitajima H et al (2002) Significance of soluble interleukin-2 receptor alpha chain in the management of patients with malignant lymphoma: a multi-center study. Rinsho Ketsueki 43:170\u2013175 (in Japanese)","journal-title":"Rinsho Ketsueki"},{"key":"5157_CR19","doi-asserted-by":"publisher","first-page":"e172","DOI":"10.1016\/j.clml.2018.12.017","volume":"19","author":"VA Morrison","year":"2019","unstructured":"Morrison VA, Shou Y, Bell JA et al (2019) Treatment Patterns and Survival Outcomes in Patients With Follicular Lymphoma: A 2007 to 2015 Humedica Database Study. Clin Lymphoma Myeloma Leuk 19:e172\u2013e183. https:\/\/doi.org\/10.1016\/j.clml.2018.12.017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"5157_CR20","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.6084\/m9.figshare.14381117","volume":"38","author":"E Bachy","year":"2021","unstructured":"Bachy E, Rufibach K, Parreira J, Launonen A, Nielsen T, Hackshaw A (2021) Phase III clinical trials in first-line follicular lymphoma: A review of their design and interpretation. Adv Ther 38:3489\u20133505. https:\/\/doi.org\/10.6084\/m9.figshare.14381117","journal-title":"Adv Ther"},{"key":"5157_CR21","doi-asserted-by":"crossref","unstructured":"Casulo C, Byrtek M, Dawson KL et al (2015) Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national lymphocare study. J Clin Oncol 33:2516\u201322. https:\/\/ascopubs.org\/doi\/full\/10.1200\/JCO.2014.59.7534. Accessed 30 Sept 2022","DOI":"10.1200\/JCO.2014.59.7534"},{"key":"5157_CR22","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1093\/annonc\/mdr145","volume":"23","author":"PL Zinzani","year":"2012","unstructured":"Zinzani PL, Tani M, Pulsoni A et al (2012) A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate\/high-risk follicular lymphoma. Ann Oncol 23:415\u2013420. https:\/\/doi.org\/10.1093\/annonc\/mdr145","journal-title":"Ann Oncol"},{"key":"5157_CR23","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/S1470-2045(08)70039-1","volume":"9","author":"PL Zinzani","year":"2008","unstructured":"Zinzani PL, Tani M, Pulsoni A et al (2008) Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). Lancet Oncol 9:352\u2013358. https:\/\/doi.org\/10.1016\/S1470-2045(08)70039-1","journal-title":"Lancet Oncol"},{"key":"5157_CR24","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3816\/CLM.2009.n.044","volume":"9","author":"JD Hainsworth","year":"2009","unstructured":"Hainsworth JD, Spigel DR, Markus TM et al (2009) Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Lymphoma Myeloma 9:223\u2013228. https:\/\/doi.org\/10.3816\/CLM.2009.n.044","journal-title":"Clin Lymphoma Myeloma"},{"key":"5157_CR25","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1007\/s11604-012-0103-6","volume":"30","author":"M Nakagawa","year":"2012","unstructured":"Nakagawa M, Uike N, Choi I, Hayashi T, Uehara S (2012) Efficacy and safety of yttrium-90 ibritumomab tiuxetan in Japanese patients with non-Hodgkin lymphoma. Jpn J Radiol 30:642\u2013647. https:\/\/doi.org\/10.1007\/s11604-012-0103-6","journal-title":"Jpn J Radiol"},{"key":"5157_CR26","doi-asserted-by":"publisher","first-page":"4336","DOI":"10.1182\/blood.V99.12.4336","volume":"99","author":"GA Wiseman","year":"2002","unstructured":"Wiseman GA, Gordon LI, Multani PS et al (2002) Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 99:4336. https:\/\/doi.org\/10.1182\/blood.V99.12.4336","journal-title":"Blood"},{"key":"5157_CR27","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1089\/cbr.2007.359","volume":"22","author":"C Emmanouilides","year":"2007","unstructured":"Emmanouilides C, Witzig TE, Wiseman GA et al (2007) Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin\u2019s lymphoma. Cancer Biother Radiopharm 22:684. https:\/\/doi.org\/10.1089\/cbr.2007.359","journal-title":"Cancer Biother Radiopharm"},{"key":"5157_CR28","doi-asserted-by":"crossref","unstructured":"Pfreundschuh M (2017) Age and sex in Non-Hodgkin lymphoma therapy: it\u2019s not all created equal, or is it? Am Soc Clin Oncol Educ Book 37:505\u2013511. https:\/\/ascopubs.org\/doi\/pdf\/10.1200\/EDBK_175447. Accessed 30 Sept 2022","DOI":"10.1200\/EDBK_175447"},{"issue":"27","key":"5157_CR29","doi-asserted-by":"publisher","first-page":"4285","DOI":"10.1200\/JCO.2006.09.2882","volume":"25","author":"MS Czuczman","year":"2007","unstructured":"Czuczman MS, Emmanouilides C, Darif M, Witzig TE, Gordon LI, Revell S, Vo K, Molina A (2007) Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol 25(27):4285\u20134292","journal-title":"J Clin Oncol"},{"issue":"3","key":"5157_CR30","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/bjh.14688","volume":"178","author":"N Epperla","year":"2017","unstructured":"Epperla N, Pham AQ, Burnette BL, Wiseman GA, Habermann TM, Macon WR, Ansell SM, Inwards DJ, Micallef IN, Johnston PB, Markovic SN, Porrata LF, Colgan JP, Ristow KM, Nowakowski GS, Witzig TE (2017) Risk of histological transformation and therapy-related myelodysplasia\/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma. Br J Haematol 178(3):427\u2013433","journal-title":"Br J Haematol"},{"issue":"3","key":"5157_CR31","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1093\/annonc\/mdf109","volume":"13","author":"C Hosing","year":"2002","unstructured":"Hosing C, Munsell M, Yazji S, Andersson B, Couriel D, de Lima M, Donato M, Gajewski J, Giralt S, K\u00f6rbling M, Martin T, Ueno NT, Champlin RE, Khouri IF (2002) Risk of therapy-related myelodysplastic syndrome\/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin\u2019s lymphoma. Ann Oncol 13(3):450\u2013459","journal-title":"Ann Oncol"},{"key":"5157_CR32","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3324\/haematol.12120","volume":"93","author":"S Sacchi","year":"2008","unstructured":"Sacchi S, Marcheselli L, Bari A et al (2008) Secondary malignancies after treatment for indolent non-Hodgkin\u2019s lymphoma: a 16-year follow-up study. Haematologica 93:398\u2013404. https:\/\/doi.org\/10.3324\/haematol.12120","journal-title":"Haematologica"},{"key":"5157_CR33","doi-asserted-by":"crossref","unstructured":"Di M, Ollila TA, Olszewski AJ (2020) Exposure to ibritumomab tiuxetan and incidence of treatment-related myeloid neoplasms among older patients with B-cell lymphoma: a population-based study. Leukemia 34:2794\u20132797. https:\/\/www.nature.com\/articles\/s41375-020-0798-9. Accessed 30 Sept 2022","DOI":"10.1038\/s41375-020-0798-9"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05157-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05157-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05157-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T06:07:15Z","timestamp":1681366035000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05157-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,30]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["5157"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05157-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,30]]},"assertion":[{"value":"7 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the ethical principles of the Declaration of Helsinki and the Ethical Guidelines for Medical and Health Research Involving Human Subjects established by the Ministry of Health, Labor, and Welfare in Japan. The study protocol was approved by the ethics committees in the all participating institutions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was not required as this study was a retrospective study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors have declared no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}